InMed Pharmaceuticals (INM) Total Debt (2021 - 2022)

InMed Pharmaceuticals (INM) reported Total Debt of $29312.0 for Q1 2022, down 50.0% quarter-over-quarter from $58624.0 in Q4 2021.

InMed Pharmaceuticals (INM) Total Debt (2021 - 2022) Analysis & Trends

InMed Pharmaceuticals has reported Total Debt for 2 years, with the latest figure at $29312.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn 16.63 Bn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn 9.05 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn -
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn 3.53 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn -
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn 3.99 Bn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn 1.51 Bn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 570.41 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn -
10 InMed Pharmaceuticals 6.00 Mn 756,271.05 - -

Historic Data

Download Data
DateValue
Mar 31, 2022 29,312.00
Dec 31, 2021 58,624.00